Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (511-520 of 751) with videos related to

Pageof 76
Sort By:
American Heart Journal|December 24, 2018
Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trialKaren P Alexander, Marc A Brouwer, Hillary Mulder, et al.
JAMA|November 6, 2022
Treatment Time and In-Hospital Mortality Among Patients With ST-Segment Elevation Myocardial Infarction, 2018-2021James G Jollis, Christopher B Granger, Jessica K Zègre-Hemsey, et al.
Circulation|September 19, 2013
Temporal differences in out-of-hospital cardiac arrest incidence and survivalAkshay Bagai, Bryan F McNally, Sana M Al-Khatib, et al.
Circulation|November 15, 2013
High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialZiad Hijazi, Agneta Siegbahn, Ulrika Andersson, et al.
Journal of the American Heart Association|September 16, 2017
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) TrialPatricia Oliveira Guimarães, Christopher B Granger, Amanda Stebbins, et al.
Circulation. Cardiovascular Interventions|January 14, 2021
Time Delay, Infarct Size, and Microvascular Obstruction After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial InfarctionBjörn Redfors, Reza Mohebi, Gennaro Giustino, et al.
Circulation. Cardiovascular Interventions|November 3, 2016
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 UpdateDominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
American Heart Journal|November 10, 2012
The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationaleChiara Melloni, Dennis L Sprecher, Lea Sarov-Blat, et al.
Cardiovascular Drugs and Therapy|May 19, 2017
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo EffectPatrícia O Guimarães, Renato D Lopes, Daniel M Wojdyla, et al.
Clinical Cardiology|November 13, 2019
Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registryStuart J Pocock, David Brieger, John Gregson, et al.
Pageof 76

Showing results (511-520 of 751) with videos related to

Sort By:
Pageof 76
American Heart Journal|December 24, 2018
Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trialKaren P Alexander, Marc A Brouwer, Hillary Mulder, et al.
JAMA|November 6, 2022
Treatment Time and In-Hospital Mortality Among Patients With ST-Segment Elevation Myocardial Infarction, 2018-2021James G Jollis, Christopher B Granger, Jessica K Zègre-Hemsey, et al.
Circulation|September 19, 2013
Temporal differences in out-of-hospital cardiac arrest incidence and survivalAkshay Bagai, Bryan F McNally, Sana M Al-Khatib, et al.
Circulation|November 15, 2013
High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialZiad Hijazi, Agneta Siegbahn, Ulrika Andersson, et al.
Journal of the American Heart Association|September 16, 2017
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) TrialPatricia Oliveira Guimarães, Christopher B Granger, Amanda Stebbins, et al.
Circulation. Cardiovascular Interventions|January 14, 2021
Time Delay, Infarct Size, and Microvascular Obstruction After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial InfarctionBjörn Redfors, Reza Mohebi, Gennaro Giustino, et al.
Circulation. Cardiovascular Interventions|November 3, 2016
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 UpdateDominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
American Heart Journal|November 10, 2012
The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationaleChiara Melloni, Dennis L Sprecher, Lea Sarov-Blat, et al.
Cardiovascular Drugs and Therapy|May 19, 2017
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo EffectPatrícia O Guimarães, Renato D Lopes, Daniel M Wojdyla, et al.
Clinical Cardiology|November 13, 2019
Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registryStuart J Pocock, David Brieger, John Gregson, et al.
Pageof 76